{'fraction_non_alphanumeric': 0.03791011855527984, 'fraction_numerical': 0.033429831816928594, 'mean_word_length': 4.725730071033938, 'pattern_counts': {'":': 0, '<': 3, '<?xml version=': 0, '>': 6, 'https://': 0, 'lorem ipsum': 0, 'www.': 0, 'xml': 0}, 'pii_count': 0, 'substrings_counts': 0, 'word_list_counts': {'cursed_substrings.json': 0, 'profanity_word_list.json': 0, 'sexual_word_list.json': 0, 'zh_pornsignals.json': 0}}
MicroRNA-122 as a predictor of HBsAg seroclearance in hepatitis B and C dual infected patients treated with interferon and ribavirin

It has been demonstrated that microRNA-122 (miR-122) plays key roles in the modulation of hepatitis B virus (HBV) replication. This study examined the role of miR-122 in patients with hepatitis C virus (HCV)-HBV dual infection with active hepatitis C who received pegylated interferon-α and ribavirin dual therapy. We enrolled 121 patients with HCV-HBV dual infection after dual therapy. Stored serum was collected before treatment. RT-PCR was used to analyze miR-122. HBsAg seroclearance was noted in 37 (30.1%) cases during a median follow-up period of 5.4 years. miR-122 was significantly lower in HBsAg seroclearance patients than in non-HBsAg seroclearance patients (P < 0.014). Multivariate analysis showed that miR-122 was an independent factor of HBsAg seroclearance (OR: 0.30, 95% CI: 0.09–0.98, P = 0.046). miR-122 was significantly higher in patients who were qHBsAg > 100 IU/mL versus ≤100 IU/mL (P < 0.001). We concluded that in patients with HBV-HCV dual infection with active hepatitis C, miR-122 was associated with HBsAg seroclearance after therapy and qHBsAg level before therapy, indicating that miR-122 plays key roles in modulating HBV replication.

In Taiwan, where patients typically acquire hepatitis B virus (HBV) infection perinatally or during early childhood, HBV and hepatitis C virus (HCV) dual infection is often the result of HCV superinfection. Seroprevalence studies have shown that concurrent HCV infection occurs in approximately 10-15% of patients with chronic HBV infection, although the prevalence may vary between areas and countries [1][2][3] .
Several studies have shown that HBV-HCV dual infection is associated with faster hepatic fibrosis progression rates, a higher risk of progression to cirrhosis, and a greater risk of hepatic decompensation and hepatocellular carcinoma development compared with HBV or HCV monoinfection 4-12 . Viral interference is evident between HBV and HCV. HCV mostly exerts a suppressive effect on HBV 1,13-15 . Liu et al. reported that combination therapy with pegylated interferon-α (Peg-IFN) and ribavirin (RBV) to eradicate HCV is equally effective in patients with HCV monoinfection and in those with chronic HCV-HBV dual infection with active hepatitis C 16 .
MicroRNAs are evolutionarily conserved, small (18-25 ribonucleotides), non-coding RNAs that have important roles in the control of many biological processes, such as cellular development, differentiation, proliferation, apoptosis, and metabolism 17 . The role of miRNAs in modulating the response to hepatotrophic virus infection has been extensively studied.
MicroRNA -122 (miR-122) is specifically expressed and highly abundant in the human liver and is thought to facilitate the replication of HCV RNA 18 . A previous study indicated that serum miR-122 levels were higher in subjects showing a sustained virological response (SVR) to Peg-IFN/RBV therapy in HCV monoinfection 19 .
Scientific RepoRts | 6:33816 | DOI: 10.1038/srep33816 Anti-miR-122 molecules reduced HCV RNA levels in a phase 2a study of G1 patients 20 . miR-122 directly suppresses HBV replication by binding to viral RNA 21,22 . Loss of miR-122 expression has also been shown to enhance HBV replication indirectly through cyclin G1-modulated p53 activity 23 . Few studies have examined the role of miR-122 in hepatitis B and C dual infection 24 . Here, we examined the role of miR-122 in patients with chronic HCV and HBV dual infection with active hepatitis C who received Peg-IFN and RBV therapy.

Patients and Methods
Patient selection. A total of 121 treatment-naïve chronic HCV-HBV dual-infected patients with active hepatitis C who received dual therapy from 2004 to 2011 and who were followed-up for more than 24 weeks after treatment were enrolled in this study. The end of follow up date is 2015-12-31. Serum hepatitis B surface antigen (HBsAg) levels were measured annually. Ultrasonography and serum α -fetoprotein (AFP) for hepatocellular carcinoma (HCC) surveillance were conducted every 6 months during the follow-up period. There were 59 genotype 1 patients and 62 genotype 2 patients. All patients received response-guided therapy irrespective of their genotype, this therapy was funded by the Bureau of National Health Insurance, Department of Health, Taiwan. The response-guided therapy was as follows: 24 weeks of PEG-IFN and RBV treatment for patients with undetectable HCV RNA at week 4 (defined as rapid virological response); 48 weeks of treatment for patients with detectable HCV RNA at week 4 and undetectable HCV RNA at week 12 (defined as early virological response); and 16 weeks for patients with detectable HCV RNA at week 12. SVR was defined as undetectable HCV RNA at follow-up week 24.
Inclusion criteria were HCV-HBV dual-infected patients with active hepatitis C, defined by seropositivity for both anti-HCV and HBsAg for more than 6 months together with detectable serum HCV-RNA (> 50 IU/mL).
Patients were excluded if they tested positive for anti-HIV antibody or exhibited other causes of hepatocellular injury (e.g., history of alcoholism, autoimmune hepatitis, primary biliary cirrhosis, or treatment with hepatotoxic drugs). The study was conducted according to the guidelines of the Declaration of Helsinki under the principles of good clinical practice and was approved by local ethics committees. Because of the observational nature of the study, we verbally informed all participants about the study, written informed consent was not required. The subject information was anonymized at collection and anonymized prior to analysis. All methods were performed in accordance with the approved guidelines.
Quantification of HBsAg and HBV DNA. HBsAg was quantified by using a standard quantitative chemiluminescent microparticle immunoassay (Architect HBsAg, Abbott Diagnostics, Princeton, NJ, USA). The concentration of HBsAg in the specimen was determined using a previously generated Architect HBsAg calibration curve (range, 0.05-250 IU/mL). Serum HBsAg < 0.05 IU/mL was defined as clearance of HBsAg. Samples with serum HBsAg titer > 250 IU/mL were diluted to 1:20 and 1:500 with the Architect HBsAg diluent and retested to expand the upper limit of the dynamic range from 250 to 125,000 IU/mL. HBV DNA levels were quantified using the Cobas Taqman assay (Roche Diagnostics, Basel, Switzerland), which has a lower limit of quantification of 60 copies/mL (12 IU/mL) and a linear range of upper detection limit of 6.4 × 10 8 copies/mL (1.3 × 10 8 IU/mL). For results exceeding the upper detection limit, HBV DNA was remeasured after 100,000-fold dilution.
HCV RNA and genotyping. Qualitative detection of HCV RNA was performed using a standardized reverse transcription polymerase chain reaction (RT-PCR) assay (Amplicor, Roche Diagnostics), using biotinylated primers for the 5′ -non-coding region. The lowest detection limit for this assay was 15 IU/mL. HCV genotyping was performed in a reverse hybridization assay (Inno-LiPA TM HCV II; Innogenetics N.V., Gent, Belgium) by using HCV-Amplicor products.
Blood sampling. Peripheral blood (PB) was collected before therapy from each individual and placed directly into serum tubes. Ethylenediaminetetraacetic acid (EDTA)-PB samples were temporarily preserved at 4 °C after collection and processed within 4 h of collection. PB samples were centrifuged at 3500 × g for 15 min to obtain the plasma, and then ammonium chloride lysis buffer (10 mM NH 4 Cl, 10 mM KHCO 3 , 0.1 mM EDTA) was used to deplete red blood cells from the PB for total leukocyte isolation. The separated plasma samples were preserved at − 20 °C until small RNA extraction.
Small RNA isolation from plasma. Isolation of small RNA from 500 μ L of plasma was performed using a mirVana ™ PARIS ™ kit (Ambion, Foster City, CA, USA) according to the manufacturer's protocols. Isolated small RNA was eluted in 100 μ L nuclease-free water. cDNAs were storage at − 20 °C in RNase free water. Real-time quantitative reverse transcription-PCR analysis of miRNAs. Mature microRNA expression was quantified by real-time quantitative RT-PCR using TaqMan ® microRNA assays according to the manufacturer's protocols (Applied Biosystems, Foster City, CA, USA), which included two steps: the RT reaction and the TaqMan real-time PCR assay. Briefly, RT reactions were performed using 10 ng of total RNA, 50 nM stem-loop microRNA-specific RT primers, 1 × RT buffer, 0.25 mM of dNTPs, 3.33 U/μ L MultiScribe RTase, and 0.25 U/μ L RNase inhibitor. The reaction mixture was incubated for 30 min at 16 °C and 30 min at 42 °C, followed by 5 min incubation at 85 °C to inactivate the RTase enzyme. RT products were subjected to microRNA expression analyses for real-time quantitative PCR in a 20-μ L final volume containing 2 μ L of RT product, 1 μ L of 20× TaqMan micro-RNA Assay (Applied Biosystems), and 10 μ L of 2× TaqMan Universal PCR Master Mix (Applied Biosystems). The PCR cycling parameters were 95 °C for 15 s followed by 60 °C for 30 s for 40 cycles. Quantitative real-time PCR was performed in triplicate. The cycle threshold (C T value) is defined as the number of cycles required for the fluorescent signal to cross the threshold in qPCR and is inversely correlated with the miRNA level. As there is currently no consensus on a suitable normalization control for serum miRNA profiling, and miR-16 has been shown to serve as a stable reference normalization control 25 , we used it as normalization control in the present study.The relative expression levels of serum miR-122 were calculated using a Δ Ct method where, Δ Ct = Ct(miR-16)-Ct(miR-122).

Discussion
In this study, we found that in patients dually infected with chronic HBV-HCV and active hepatitis C, the baseline miR-122 level was correlated with qHBsAg levels at baseline and could be used to predict HBsAg seroclearance after Peg-IFN and RBV treatment. Previous studies demonstrated that the serum miR-122 level may predict HCV SVR in patients with genotype 2 HCV monoinfection 19 . In this study, we found that miR-122 was not associated with SVR according to multivariate analysis. Since the number of cases in this study was small, including only 62 genotype 2 dual-infected patients, further studies of a larger number of subjects is needed to explore the association between the miR-122 level and HCV SVR. HBs antigen and HBV DNA levels were quantified as surrogate parameters for HBV replication and translation. Previous studies evaluating chronic hepatitis B monoinfected patients revealed a positive correlation between miR-122 expression and HBV DNA [26][27][28][29] , miR-122 was positively correlated to the HBsAg titer [27][28][29] , and   miR-122 levels were significantly higher in HBeAg-positive patients than in HBeAg-negative patients 28 . These findings obtained from HBV monoinfected patients were similar to those from hepatitis B and C dual-infected patients in our study. Although the reason for the higher levels of miR-122 in patients with active HBV replication is unclear, the innate immune response in liver cells against HBV replication may induce higher expression of miR-122, which can be reflected in serum levels 28 . The other explanation is that miR-122 may passively leak from damaged or dying cells because of apoptosis or necrosis. HBV-induced cell damage involves a combination of HBV-induced apoptotic and T cell-induced cell death 30 . Circulating miR-122 has been described as a sensitive marker of hepatocyte damage, and thus may originate from dying cells 31 . Studies related to serum microRNAs in chronic hepatitis B-or C-infected patients have been widely reported. However, few studies have examined serum microRNAs in chronic dual HBV-HCV-infected patients 24 . Cheng et al. evaluated 76 patients with HBV/HCV dual-infection who received Peg-IFN-based treatment. In multivariate analysis, the serum miR-122 level was positively correlated with serum qHBsAg. A high baseline miR-122 level was positively correlated with a greater reduction in the post-treatment serum qHBsAg level 24 . In our study, we also found that miR122 was significantly higher in patients with qHBsAg > 100 IU/mL. Cheng et al. also observed HBsAg seroclearance in 14 patients after a 6-month follow-up post-PEG-IFN-based treatment. The miR-122 level was not correlated with HBsAg seroclearance 24 . In contrast, we found that miR-122 was independently correlated with HBsAg seroclearance. The discrepancy may be that Cheng et al. only evaluated HBsAg seroclearance at 6 months after treatment. However, we determined HBsAg seroclearance annually after treatment over a longer follow-up (median 5.4 years).
HBsAg seroclearance typically confers a favorable outcome and is the optimal treatment goal. However, HBsAg seroclearance is very rarely observed in HBV mono-infected patients receiving currently available antiviral agents, with an annual rate of 2.4-3.2% with IFN or Peg-IFN therapy and only 1% with nucleoside/nucleotide analogues 32,33 . Previous studies showed that 25.6-30% of HBV/HCV dually infected patients treated with PEG-IFN/RBV combination therapy achieved HBsAg seroclearance during the 5-year follow-up period 34,35 , which agrees with the results of our study. This higher rate of HBsAg seroclearance suggests that viral interaction between HBV and HCV influences the rate of HBsAg seroclearance.
Factors related to HBsAg seroclearance in hepatitis B and C dual infection include liver cirrhosis and HBV DNA negativity at 1 year after end-of-treatment 34 , low baseline serum HBV DNA 34 , and low baseline HBsAg levels 16,35,36 . In our study, multivariate analysis showed that male, age > 60 years, ALT > 80 IU/L, qHBsAg ≤ 100 IU/ml and low miR-122 levels were independently correlated with HBsAg seroclearance. The possible mechanism of this novel finding is unclear, but miR-122 may play a key role in modulating HBV replication in the viral interaction with HCV [21][22][23] .
Although previous studies showed that miR-122 was associated with HCC 37-39 , miR-122 was not associated with HCC development in our study.
In conclusion, for patients with chronic HBV-HCV dual infection and active hepatitis C, baseline miR-122 was correlated with baseline qHBsAg level and independently predicted HBsAg seroclearance after Peg-IFN and RBV treatment. Further long-term and large-scale studies are warranted.